CN115968312A - 用于治疗强迫症的组合物和方法 - Google Patents

用于治疗强迫症的组合物和方法 Download PDF

Info

Publication number
CN115968312A
CN115968312A CN202180044180.1A CN202180044180A CN115968312A CN 115968312 A CN115968312 A CN 115968312A CN 202180044180 A CN202180044180 A CN 202180044180A CN 115968312 A CN115968312 A CN 115968312A
Authority
CN
China
Prior art keywords
dosage form
patient
weeks
week
bocs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044180.1A
Other languages
English (en)
Chinese (zh)
Inventor
V·克瑞克
R·伯曼
L·阿吉亚尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of CN115968312A publication Critical patent/CN115968312A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180044180.1A 2020-06-24 2021-06-24 用于治疗强迫症的组合物和方法 Pending CN115968312A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
US63/043,681 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (1)

Publication Number Publication Date
CN115968312A true CN115968312A (zh) 2023-04-14

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044180.1A Pending CN115968312A (zh) 2020-06-24 2021-06-24 用于治疗强迫症的组合物和方法

Country Status (12)

Country Link
US (1) US20230181541A1 (https=)
EP (1) EP4171554A4 (https=)
JP (1) JP7805969B2 (https=)
KR (1) KR20230027189A (https=)
CN (1) CN115968312A (https=)
AU (1) AU2021297249A1 (https=)
BR (1) BR112022025901A2 (https=)
CA (1) CA3187323A1 (https=)
IL (1) IL299301A (https=)
MX (1) MX2022016174A (https=)
PH (1) PH12022553441A1 (https=)
WO (1) WO2021262914A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107567438A (zh) * 2015-03-03 2018-01-09 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
US20190255061A1 (en) * 2018-02-21 2019-08-22 Al Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US20190321317A1 (en) * 2015-05-22 2019-10-24 Vistagen Therapeutics, Inc. Therapeutic uses of l-4-chlorokynurenine
WO2019231865A1 (en) * 2018-05-27 2019-12-05 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole oral disintigrating tablets for treating diseases
WO2020023324A1 (en) * 2018-07-22 2020-01-30 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2020037152A1 (en) * 2018-08-16 2020-02-20 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107567438A (zh) * 2015-03-03 2018-01-09 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
US20200085794A1 (en) * 2015-03-03 2020-03-19 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
US20190321317A1 (en) * 2015-05-22 2019-10-24 Vistagen Therapeutics, Inc. Therapeutic uses of l-4-chlorokynurenine
US20190255061A1 (en) * 2018-02-21 2019-08-22 Al Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
WO2019231865A1 (en) * 2018-05-27 2019-12-05 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole oral disintigrating tablets for treating diseases
WO2020023324A1 (en) * 2018-07-22 2020-01-30 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2020037152A1 (en) * 2018-08-16 2020-02-20 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD: "Biohaven Announces ObsessiveCompulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update", 《HTTPS://WWW.PRNEWSWIRE.COM/NEWS-RELEASES/BIOHAVEN-ANNOUNCES-OBSESSIVE-COMPULSIVE-DISORDER-OCD-PROOF-OF-CONCEPT-PHASE-23-STUDY-RESULTS-AND-PROGRAM-UPDATE-301082586.HTML》, 24 June 2020 (2020-06-24), pages 1 - 5 *
CLINICALTRIALS.GOV: "Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder", 《HTTPS://CLINICALTRIALS.GOV/STUDY/NCT03299166?TAB=HISTORY&A=62#VERSION-CONTENT-PANEL》, 13 May 2020 (2020-05-13), pages 1 - 19 *

Also Published As

Publication number Publication date
AU2021297249A1 (en) 2023-02-23
BR112022025901A2 (pt) 2023-01-10
WO2021262914A1 (en) 2021-12-30
IL299301A (en) 2023-02-01
EP4171554A1 (en) 2023-05-03
US20230181541A1 (en) 2023-06-15
PH12022553441A1 (en) 2024-03-04
MX2022016174A (es) 2023-01-24
CA3187323A1 (en) 2021-12-30
KR20230027189A (ko) 2023-02-27
JP2023531919A (ja) 2023-07-26
JP7805969B2 (ja) 2026-01-26
EP4171554A4 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
Goldstein et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy
US20220152055A1 (en) Methods and compositions for treating various disorders
Weihs et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression
Horton Albendazole in treatment of human cystic echinococcosis: 12 years of experience
Carbone et al. Impulse control disorders in Parkinson’s disease: an overview of risk factors, pathogenesis and pharmacological management
JP2024543053A (ja) 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
Lindsay et al. Use of modafinil for the treatment of attention deficit/hyperactivity disorder
CN115968312A (zh) 用于治疗强迫症的组合物和方法
Sloane et al. The use of imipramine (tofranil) for depressive states in open ward settings of a general hospital: a preliminary report
KR20240093852A (ko) 중등도 내지 중증의 불안 및/또는 사회적 회피를 갖는 자폐 스펙트럼 장애가 있는 대상체에서의 과민성 치료
US20220401391A1 (en) Methods and compositions for treating pain
JP2008260728A (ja) 線維筋痛症治療薬
Turedi et al. First time, low dose citalopram use-related serotonin syndrome
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
US20240358693A1 (en) Methods of treating pain
McCleane et al. Clinical management of the elderly patient in pain
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
WO2023036820A1 (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
CN118613265A (zh) 用于治疗神经变性疾病的胆汁酸和苯基丁酸化合物的组合
González-Pinto et al. P. 2. e. 016 Antipsychotic treatments during acute mania with prominent aggressive behaviour
Mak The diagnosis and management of obsessive compulsive disorders in primary care

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination